Canakinumab is a recombinant human anti-IL-1_ monoclonal antibody used for the treatment of immune disorders such as rheumatoid arthritis and cryopyrin-associated periodic syndrome (CAPS).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.